Published in J Clin Invest on November 01, 1975
Human hypoxanthine-guanine phosphoribosyltransferase. Demonstration of structural variants in lymphoblastoid cells derived from patients with a deficiency of the enzyme. J Clin Invest (1982) 1.65
A molecular survey of hypoxanthine-guanine phosphoribosyltransferase deficiency in man. J Clin Invest (1986) 1.28
Human hypoxanthine-guanine phosphoribosyltransferase. Detection of a mutant allele by restriction endonuclease analysis. J Clin Invest (1983) 0.88
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
A method for determining the sedimentation behavior of enzymes: application to protein mixtures. J Biol Chem (1961) 59.20
Determination of molecular weights and frictional ratios of proteins in impure systems by use of gel filtration and density gradient centrifugation. Application to crude preparations of sulfite and hydroxylamine reductases. Biochim Biophys Acta (1966) 16.27
A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION. Am J Med (1964) 7.97
THE RENAL CLEARANCE OF ENDOGENOUS "CREATININE" IN MAN. J Clin Invest (1948) 7.93
Isoelectric fractionation, analysis, and characterization of ampholytes in natural pH gradients. IV. Further studies on the resolving power in connection with separation of myoglobins. Acta Chem Scand (1966) 7.93
THREE DEGREES OF GUANYLIC ACID--INOSINIC ACID PYROPHOSPHORYLASE DEFICIENCY IN MOUSE FIBROBLASTS. Nature (1964) 4.67
DETERMINATION OF DENSITY DISTRIBUTION OF RED CELL POPULATION. J Lab Clin Med (1964) 3.67
Uric acid production in gout. J Clin Invest (1961) 3.62
A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci U S A (1967) 3.29
Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern Med (1969) 2.84
Altered enzymes in drug-resistant variants of mammalian tissue culture cells. Proc Natl Acad Sci U S A (1973) 2.24
Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem (1968) 2.08
Human hypoxanthine phosphoribosyltransferase. I. Purification, properties, and specificity. J Biol Chem (1969) 2.01
Mutations affecting the structure of hypoxanthine: guanine phosphoribosyltransferase in cultured Chinese hamster cells. Proc Natl Acad Sci U S A (1973) 1.78
Urine uric acid to creatinine rtio--a screening test for inherited disorders of purine metabolism. Phosphoribosyltransferase (PRT) deficiency in X-linked cerebral palsy and in a variant of gout. J Pediatr (1968) 1.76
Selective degradation of abnormal proteins in mammalian tissue culture cells. Proc Natl Acad Sci U S A (1974) 1.66
The spontaneous azaguanine-resistant mutants of diploid human fibroblasts. Humangenetik (1972) 1.65
An enzymatic spectrophotometric method for the determination of xanthine and hypoxanthine. Clin Chem (1967) 1.57
Lesch-Nyhan syndrome: altered kinetic properties of mutant enzyme. Science (1971) 1.56
An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency. N Engl J Med (1968) 1.45
Studies on hypoxanthine-guanine phosphoribosyltransferase in fibroblasts from patients with the Lesch-Nyhan syndrome. Evidence for genetic heterogeneity. J Biol Chem (1971) 1.43
Human hypoxanthine-guanine phosphoribosyltransferase. Purification and subunit structure. J Biol Chem (1971) 1.42
Human phosphoribosylpyrophosphate synthetase. Distribution, purification, and properties. J Biol Chem (1971) 1.38
Purification of IMP:pyrophosphate phosphoribosyltransferases, catalytically incompetent enzymes in Lesch-Nyhan disease. Proc Natl Acad Sci U S A (1971) 1.36
Inherited disorder of purine metabolism. Correlation between central nervous system dysfunction and biochemical defects. JAMA (1967) 1.34
Kinetic studies of hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem (1968) 1.28
Phosphoribosylpyrophosphate in man: biochemical and clinical significance. Ann Intern Med (1971) 1.28
Hypoxanthine-guanine phosphoribosyltransferase: characteristics of the mutant enzyme in erythrocytes from patients with the Lesch-Nyhan syndrome. J Clin Invest (1972) 1.21
The spectrum of hypoxanthine-guanine phosphoribosyltransferase deficiency. Q J Med (1973) 1.17
Human adenine phosphoribosyltransferase. Purification, subunit structure, and substrate specificity. J Biol Chem (1973) 1.11
Chinese hamster hypoxanthine-guanine phosphoribosyltransferase. Purification, structural, and catalytic properties. J Biol Chem (1974) 1.08
Depletion of erythrocyte phosphoribosylpyrophosphate in man. N Engl J Med (1970) 1.05
The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism. J Clin Invest (1967) 1.04
Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase: intermediate enzyme deficiency in heterozygote red cells. Ann Intern Med (1972) 1.01
Disparate enzyme activity in erythocytes and leukocytes. A variant of hypoxanthine phosphoribosyl-transferase deficiency with an unstable enzyme. J Clin Invest (1973) 0.99
Nature of mutations conferring resistance to 8-azaguanine in mouse cell lines. J Cell Sci (1974) 0.99
Isoenzymes of hypoxanthine-guanine-phosphoribosyl transferase in a family with partial deficiency of the enzyme. Biochem Genet (1972) 0.98
Rarity of X-linked partial hypoxanthine-guanine phosphoribosyltransferase deficiency in a large gouty population. Ann Intern Med (1972) 0.97
Subunit molecular weight of human hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem (1974) 0.94
Purification and characterization of mouse hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem (1975) 0.93
Disorder of purine metabolism due to partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. A study of a family. Am J Med (1970) 0.91
Interallelic complementation in hybrid cells derived from Chinese hamster diploid clones deficient in hypoxanthine-guanine phosphoribosyl-transferase activity. Exp Cell Res (1973) 0.90
Purine nucleotide pyrophosphorylases in 8-azaguanine-sensitive and-resistant P388 leukemias. J Natl Cancer Inst (1962) 0.89
Accelerated turnover of phosphoribosylpyrophosphate, a purine nucleotide precursor, in certain gouty subjects. J Clin Invest (1962) 0.89
Human hypoxanthine-guanine phosphoribosyltransferase: studies on the normal and mutant forms of the enzyme. Fed Proc (1973) 0.86
Excretion of hypoxanthine and xanthine in a genetic disease of purine metabolism. Nature (1967) 0.85
Increased formation of 5-phosphoriboxyl-1-pyrophosphate in red blood cells of some gouty patients. Isr J Med Sci (1969) 0.84
Human hypoxanthine phosphoribosyltransferase. II. Kinetics and chemical modification. J Biol Chem (1969) 0.82
Hypoxanthine-guanine phosphoribosyltransferase variant associated with accelerated purine synthesis. J Clin Invest (1973) 0.82
Diploid azaguanine-resistant mutants of cultured human fibroblasts. Science (1970) 0.78
Chinese hamster cells exhibiting a temperature dependent alteration in purine transport. J Cell Physiol (1974) 0.78
Heterogeneity in the biochemical characteristics of red blood cell hypoxanthine-guanine phosphoribosyl transferase from two unrelated patients with the Lesch-Nyhan syndrome. Biochem Genet (1973) 0.77
Evidence for molecular alteration of erythrocyte hypoxanthine-guanine phosphoribosyltransferase in a gouty family with partial deficiency of the enzyme. Rev Eur Etud Clin Biol (1972) 0.77
Analysis of human hypoxanthine-guanine phosphoribosyl transferase isozymes by isoelectric focusing in polyacrylamide gel. Biochem Genet (1973) 0.76
Increased activity of two enzymes of pyrimidine biosynthesis de novo in erythrocytes from patients with the Lesch-Nyhan syndrome. J Lab Clin Med (1973) 0.76
Possible functions of hypoxanthine-guanine phosphoribosyltransferase and their relation to the biochemical pathology of the Lesch-Nyhan syndrome. Fed Proc (1968) 0.76
Microscale isoelectric focusing studies of mouse and human hypoxanthine-guanine phosphoribosyl transferases. Biochem Genet (1973) 0.76
Degradation of CFTR by the ubiquitin-proteasome pathway. Cell (1995) 7.88
Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother (1979) 5.88
The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev (1976) 4.11
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res (1996) 3.37
Inhibition of fatty acid synthesis by the antibiotic cerulenin. Specific inactivation of beta-ketoacyl-acyl carrier protein synthetase. Biochim Biophys Acta (1973) 3.10
Blood-lead and hypertension. Lancet (1976) 2.82
Major vascular injuries during gynecologic laparoscopy. J Am Coll Surg (1997) 2.50
The role of adenosine and 2'-deoxyadenosine in mammalian cells. Annu Rev Biochem (1978) 2.49
Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol Cell Biol (1997) 2.43
Environmental lead pollution in an urban soft-water area. Br Med J (1972) 2.28
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem (1996) 2.19
Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother (1998) 2.07
Production of 'hybrid' antibiotics by genetic engineering. Nature (1985) 2.04
Studies on penicillinase inhibitors produced by microorganisms. J Antibiot (Tokyo) (1972) 2.04
Organization of the biosynthetic gene cluster for the polyketide anthelmintic macrolide avermectin in Streptomyces avermitilis. Proc Natl Acad Sci U S A (1999) 1.98
Binding site of cerulenin in fatty acid synthetase. J Biochem (1989) 1.98
A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiot (Tokyo) (1977) 1.92
Cerulenin. Methods Enzymol (1981) 1.92
Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q J Med (1977) 1.91
The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun (1990) 1.88
The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J Biol Chem (1997) 1.87
Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot (Tokyo) (1991) 1.86
Heme oxygenase-1 protects against radiocontrast-induced acute kidney injury by regulating anti-apoptotic proteins. Kidney Int (2007) 1.80
Tin protoporphyrin prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria. Gastroenterology (1993) 1.76
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer (1998) 1.75
Controlled trial of haem arginate in acute hepatic porphyria. Lancet (1989) 1.75
Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J Antibiot (Tokyo) (1984) 1.71
Low level exposure to lead. BMJ (1990) 1.67
Studies on the mechanism of fructose-induced hyperuricemia in man. Metabolism (1972) 1.67
Cyclosporine-induced hyperuricemia and gout. N Engl J Med (1989) 1.67
Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med (1982) 1.64
The action mechanism of cerulenin. I. Effect of cerulenin on sterol and fatty acid biosynthesis in yeast. J Biochem (1972) 1.58
Acromegalic arthropathy. Characteristics and response to therapy. Arthritis Rheum (1988) 1.54
Lymphocyte ecto-5'-nucleotidase deficiency in agammaglobulinemia. Science (1978) 1.53
Target of inhibition by the anti-lipogenic antibiotic cerulenin of sterol synthesis in yeast. Biochem Biophys Res Commun (1974) 1.52
Life satisfaction and quality in Korean War veterans five decades after the war. J Epidemiol Community Health (2009) 1.48
Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med (1981) 1.48
Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway. J Biol Chem (1995) 1.46
Depression of delta-aminolaevulic acid dehydrase activity by ethanol in man and rat. Clin Sci (1971) 1.45
Purine metabolism during strenuous muscular exercise in man. Metabolism (1980) 1.44
Re-assessment of risk factors for sporadic Salmonella serotype Enteritidis infections: a case-control study in five FoodNet Sites, 2002-2003. Epidemiol Infect (2006) 1.43
Complete inhibition of human immunodeficiency virus Gag myristoylation is necessary for inhibition of particle budding. J Biol Chem (1996) 1.43
How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med (2000) 1.41
Progressive rheumatoid arthritis: how far should we go with medical therapy? Can Med Assoc J (1980) 1.40
Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun (1996) 1.40
Role of chronic low-level lead exposure in the aetiology of mental retardation. Lancet (1975) 1.39
Agroactive compounds of microbial origin. Annu Rev Microbiol (1993) 1.38
Human phosphoribosylpyrophosphate synthetase. Distribution, purification, and properties. J Biol Chem (1971) 1.38
Metabolic basis for disorders of purine nucleotide degradation. Metabolism (1981) 1.36
Human phosphoribosylpyrophosphate synthetase. Kinetic mechanism and end product inhibition. J Biol Chem (1972) 1.36
Acute intermittent porphyria: response of tachycardia and hypertension to propranolol. Br Med J (1973) 1.35
Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot (Tokyo) (1991) 1.34
Cloning, sequencing and deduced functions of a cluster of Streptomyces genes probably encoding biosynthesis of the polyketide antibiotic frenolicin. Gene (1994) 1.31
Inhibition of acyl-CoA synthetase by triacsins. Biochim Biophys Acta (1987) 1.31
Genetic studies of avermectin biosynthesis in Streptomyces avermitilis. J Bacteriol (1987) 1.31
Relationship of net chloride flow across the human erythrocyte membrane to the anion exchange mechanism. J Gen Physiol (1983) 1.30
Renal insufficiency associated with excessive lead exposure. Br Med J (1977) 1.29
Treatment with haematin in acute hepatic porphyria. Q J Med (1981) 1.29
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun (1995) 1.29
In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64. J Pharmacobiodyn (1986) 1.29
Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase. Proc Natl Acad Sci U S A (1979) 1.28
Phosphoribosylpyrophosphate in man: biochemical and clinical significance. Ann Intern Med (1971) 1.28
Degradation of 3-hydroxy-3-methylglutaryl-CoA reductase in endoplasmic reticulum membranes is accelerated as a result of increased susceptibility to proteolysis. J Biol Chem (1996) 1.26
Amphomycin inhibits phospho-N-acetylmuramyl-pentapeptide translocase in peptidoglycan synthesis of Bacillus. Biochem Biophys Res Commun (1979) 1.26
Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun (1997) 1.26
Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors. J Gen Virol (1997) 1.25
Clinical and radiographic abnormalities in ankylosing spondylitis: a comparison of men and women. Radiology (1976) 1.24
mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ (1998) 1.23
Chronic peroxisome proliferation and hepatomegaly associated with the hepatocellular tumorigenesis of di(2-ethylhexyl)phthalate and the effects of recovery. Toxicol Sci (1999) 1.23
The neurotoxicology of lead. Neurotoxicology (1986) 1.22
Hyperuricemia: a marker for cell energy crisis. N Engl J Med (1987) 1.21
Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Proc Natl Acad Sci U S A (1996) 1.20
Inhibition of acyl-CoA: cholesterol acyltransferase activity by cyclodepsipeptide antibiotics. J Antibiot (Tokyo) (1992) 1.20
Computer-assisted interactive three-dimensional planning for neurosurgical procedures. Neurosurgery (1996) 1.19
Induction of delta-aminolaevulinic acid synthase in leucocytes of patients on phenytoin therapy--comparison with changes in rat hepatic tissue. Br J Clin Pharmacol (1980) 1.19
Tetraethyl-lead poisoning. Lancet (1972) 1.18
Structures and biological properties of Kinamycin A, B, C, and D. Chem Pharm Bull (Tokyo) (1973) 1.18
Revised structure of cerulenin. J Antibiot (Tokyo) (1974) 1.17
Transposon mutagenesis by Tn4560 and applications with avermectin-producing Streptomyces avermitilis. J Bacteriol (1993) 1.17
A new antibiotic, kinamycin. J Antibiot (Tokyo) (1970) 1.16
Screening for latent acute intermittent porphyria: the value of measuring both leucocyte delta-aminolaevulinic acid synthase and erythrocyte uroporphyrinogen-1-synthase activities. J Med Genet (1982) 1.15
Herbimycin, a new antibiotic produced by a strain of Streptomyces. J Antibiot (Tokyo) (1979) 1.15
Activation of atypical protein kinase C zeta by caspase processing and degradation by the ubiquitin-proteasome system. J Biol Chem (2000) 1.15
[Contribution of lead in drinking water to blood-lead]. Lancet (1977) 1.15
MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients. Cancer (1973) 1.14
Heme biosynthesis in Friend erythroleukemia cells: control by ferrochelatase. Proc Natl Acad Sci U S A (1979) 1.14
Papain inhibitions by optically active E-64 analogs. J Biochem (1981) 1.14
Food iron and lead absorption in humans. Am J Clin Nutr (1986) 1.13
Effect of certain anaesthetic agents on the activity of rat hepatic delta-aminolaevulinate synthase. Br J Anaesth (1978) 1.13
Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine. Arthritis Rheum (1977) 1.13
Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by Bcl-2. J Biol Chem (1998) 1.13
A new antibiotic, kinamycin: fermentation, isolation, purification and properties. J Antibiot (Tokyo) (1971) 1.12
Various Bacillus Typhosus Antigens Used for the Macroscopic Widal. Am J Public Health Nations Health (1935) 1.12
Chemical and biological studies on 16-membered macrolide antibiotics. J Antibiot (Tokyo) (1975) 1.12
Evidence for an essential role of long chain acyl-CoA synthetase in animal cell proliferation. Inhibition of long chain acyl-CoA synthetase by triacsins caused inhibition of Raji cell proliferation. J Biol Chem (1991) 1.12
Triacsins, new inhibitors of acyl-CoA synthetase produced by Streptomyces sp. J Antibiot (Tokyo) (1986) 1.11
Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial. N Engl J Med (1983) 1.11
New antitumor antibiotics, OS-4742 A1, A2, B1 and B2 produced by a strain of Streptomyces. J Antibiot (Tokyo) (1977) 1.11